INVESTOR ALERT: Investigation of Ocular Therapeutix, Inc. Announced by Law Offices of Howard G. Smith

Law Offices of Howard G. Smith announces an investigation on behalf of investors of Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (NASDAQ: OCUL) concerning the Company and its officers’ possible violations of federal securities laws.

Ocular is a biopharmaceutical company that focuses on the development and commercialization of therapies for diseases and conditions of the eye by using its proprietary hydrogel platform technology.

Specifically, the investigation concerns Ocular’s disclosure on July 25, 2016, announcing that the U.S. Food and Drug Administration (“FDA”) had denied approval for the Company’s treatment of post-operative eye pain after an inspection of one of the Company’s facilities.

On this news, Ocular’s share price has fell over 10% during intraday trading on July 25, 2016.

If you purchased Ocular securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160727006374/en/